Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) EBT Margin (2017 - 2025)

Sutro Biopharma (STRO) has disclosed EBT Margin for 9 consecutive years, with 2186.89% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 114017.0% to 2186.89% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.41% through Dec 2025, changed N/A year-over-year, with the annual reading at 57.63% for FY2023, 11457.0% up from the prior year.
  • EBT Margin hit 2186.89% in Q4 2025 for Sutro Biopharma, up from 586.58% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 2186.89% in Q4 2025 to a low of 1146.05% in Q1 2025.
  • Historically, EBT Margin has averaged 145.42% across 5 years, with a median of 319.09% in 2021.
  • Biggest YoY gain for EBT Margin was 114017bps in 2025; the steepest drop was -69854bps in 2025.
  • Year by year, EBT Margin stood at 357.85% in 2021, then fell by -12bps to 400.76% in 2022, then skyrocketed by 110bps to 41.22% in 2023, then soared by 2440bps to 1046.73% in 2024, then soared by 109bps to 2186.89% in 2025.
  • Business Quant data shows EBT Margin for STRO at 2186.89% in Q4 2025, 586.58% in Q3 2025, and 18.07% in Q2 2025.